Article date: October 2018
By: Cornelius F. Waller, Apinya Vutikullird, Tracey E. Lawrence, Andrew Shaw, Mark Shiyao Liu, Mark Baczkowski, Rajiv Sharma, Abhijit Barve, Parag Goyal, Charles Donnelly, Nilanjan Sengupta, Eduardo J. Pennella in Volume 84, Issue 10, pages 2336-2343
Aims
Trastuzumab is a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2) oncoprotein and is an effective therapy for HER2‐overexpressing breast cancer. MYL‐1401O is a trastuzumab biosimilar. Here, we report results from a phase 1 study that investigated bioequivalence among MYL‐1401O, reference EU‐trastuzumab and US‐trastuzumab.
Methods
This single‐centre, randomized, double‐blind, three‐arm, parallel‐group, phase 1 study was conducted in healthy adult male volunteers. Subjects were randomized 1:1:1 to receive a single 8 mg kg−1 dose of MYL‐1401O, EU‐trastuzumab or US‐trastuzumab as a 90‐min intravenous infusion. The primary objective was to assess PK similarity among all three products. Primary endpoints assessed were peak serum concentration (Cmax), area under the serum concentration–time curve from time of dosing to time of last quantifiable concentration and from time of dosing to infinity. Secondary endpoints included time of Cmax, elimination rate constant, half‐life, safety and immunogenicity.
Results
Of 132 subjects enrolled (44/treatment), 120 (MYL‐1401O, n = 42; EU‐trastuzumab, n = 41; US‐trastuzumab, n = 37) were included in the PK analysis. The 90% confidence intervals of the ratios of geometric means for the primary endpoints were bounded within the predefined bioequivalence criterion of 80–125%. Secondary endpoints time of Cmax, elimination rate constant and half‐life were similar among groups. All treatment‐emergent adverse events were mild or moderate, similar across groups and no serious adverse events were reported. No treatment‐related antidrug antibodies were detected.
Conclusions
MYL‐1401O was well tolerated and demonstrated PK and safety profiles similar to EU‐trastuzumab and US‐trastuzumab in healthy volunteers (ClinicalTrials.gov, NCT02594761).
DOI: 10.1111/bcp.13689
View this article